Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H1 2017

  • ID: 4315558
  • Report
  • 54 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AngioChem Inc
  • ArmaGen Inc
  • Bioasis Technologies Inc
  • Green Cross Corp
  • RegenxBio Inc
  • Sangamo Therapeutics Inc
  • MORE
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H1 2017

Summary:

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) pipeline Target constitutes close to 12 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The latest report Iduronate 2 Sulfatase - Pipeline Review, H1 2017, outlays comprehensive information on the Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Iduronate 2-sulfatase (IDS) is a sulfatase enzyme associated with Hunter syndrome. Iduronate 2-sulfatase is required for the lysosomal degradation of heparan sulfate and dermatan sulfate. Mutations in this X-chromosome gene that result in enzymatic deficiency lead to Hunter syndrome. The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 4, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Genetic Disorders and Central Nervous System which include indications Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) and Cognitive Impairment.

Furthermore, this report also reviews key players involved in Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13)
  • The report reviews Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AngioChem Inc
  • ArmaGen Inc
  • Bioasis Technologies Inc
  • Green Cross Corp
  • RegenxBio Inc
  • Sangamo Therapeutics Inc
  • MORE
  1. Introduction
  2. Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Overview
  3. Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Therapeutics Development
  4. Products under Development by Stage of Development
  5. Products under Development by Therapy Area
  6. Products under Development by Indication
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Therapeutics Assessment
  10. Assessment by Mechanism of Action
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Companies Involved in Therapeutics Development
  14. AngioChem Inc
  15. ArmaGen Inc
  16. Bioasis Technologies Inc
  17. Green Cross Corp
  18. JCR Pharmaceuticals Co Ltd
  19. Laboratorios Del Dr Esteve SA
  20. RegenxBio Inc
  21. Sangamo Therapeutics Inc
  22. Shire Plc
  23. Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Drug Profiles
  24. AGT-182 - Drug Profile
  25. Product Description
  26. Mechanism Of Action
  27. R&D Progress
  28. EGT-301 - Drug Profile
  29. Product Description
  30. Mechanism Of Action
  31. R&D Progress
  32. Gene Therapy to Activate Iduronate 2 Sulfatase for Mucopolysaccharidosis II - Drug Profile
  33. Product Description
  34. Mechanism Of Action
  35. R&D Progress
  36. idursulfase - Drug Profile
  37. Product Description
  38. Mechanism Of Action
  39. R&D Progress
  40. idursulfase beta - Drug Profile
  41. Product Description
  42. Mechanism Of Action
  43. R&D Progress
  44. JR-032 - Drug Profile
  45. Product Description
  46. Mechanism Of Action
  47. R&D Progress
  48. JR-141 - Drug Profile
  49. Product Description
  50. Mechanism Of Action
  51. R&D Progress
  52. MTf-I2S - Drug Profile
  53. Product Description
  54. Mechanism Of Action
  55. R&D Progress
  56. MTfp-I2S - Drug Profile
  57. Product Description
  58. Mechanism Of Action
  59. R&D Progress
  60. Recombinant Iduronate 2-Sulfatase Replacement for Mucopolysaccharidosis II - Drug Profile
  61. Product Description
  62. Mechanism Of Action
  63. R&D Progress
  64. RGX-121 - Drug Profile
  65. Product Description
  66. Mechanism Of Action
  67. R&D Progress
  68. SB-913 - Drug Profile
  69. Product Description
  70. Mechanism Of Action
  71. R&D Progress
  72. Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Product Development Milestones
  73. Featured News & Press Releases
  74. May 04, 2017: Sangamo Therapeutics Announces Rare Pediatric Disease Designation for SB-913 In Vivo Genome Editing Treatment for MPS II
  75. Mar 01, 2017: Sangamo Therapeutics Receives Orphan Drug Designation from the FDA for SB-913 Genome Editing Treatment for MPS II
  76. Feb 08, 2017: Sangamo Therapeutics Announces Data on SB-913 at The 13th Annual WORLDSymposium Meeting
  77. Oct 26, 2016: National Center for Child Health and Development Initiates Phase 1/2 Trial of Green Cross' idursulfase-beta ICV for the Treatment of Hunter Syndrome with Neurocognitive Decline
  78. Sep 13, 2016: REGENXBIO Publishes Data from Ongoing Preclinical Studies of NAV Gene Therapy RGX-121
  79. Jul 14, 2016: ArmaGen Presents Data from First Cohort of Phase 1/2a of AGT-182 for Treatment of Hunter Syndrome
  80. Jul 05, 2016: REGENXBIO Provides Update On Gene Therapy Development Program RGX-121
  81. Jun 20, 2016: Sangamo BioSciences Announces FDA Clearance of Investigational New Drug Application for ZFN-Mediated Genome Editing Treatment of MPS II
  82. Apr 19, 2016: Preclinical Data from REGENXBIO’s RGX-121 Gene Therapy Program to be Presented at the American Society of Gene & Cell Therapy 19th Annual Meeting
  83. Feb 25, 2016: ESTEVE Provides Update On EGT-301 For Hunter Syndrome
  84. Jul 31, 2015: biOasis Announces the Successful Delivery to the CNS of an Enzyme used to Treat Hunter Syndrome
  85. Jun 23, 2015: ACTSI-supports first-in-man clinical trial for Hunter syndrome at Emory University Hospital
  86. Jun 15, 2015: ArmaGen Achieves Clinical Milestone in Hunter Syndrome Collaboration with Shire
  87. Mar 10, 2015: PacificGMP and ArmaGen Announce Successful Manufacture of ArmaGen's investigational enzyme replacement therapy, AGT-182, for Phase 1 Clinical Trial
  88. Jan 26, 2015: Shire's Investigational SHP609, idursulfase-IT, Receives FDA Fast Track Designation for the Treatment of Neurocognitive Decline Associated with Hunter Syndrome
  89. Appendix
  90. Methodology
  91. Coverage
  92. Secondary Research
  93. Primary Research
  94. Expert Panel Validation
  95. Contact Us
  96. Disclaimer
List of Tables:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Indication, H1
  4. Number of Products under Development by Companies, H1
  5. Products under Development by Companies, H1
  6. Number of Products under Investigation by Universities/Institutes, H1
  7. Products under Investigation by Universities/Institutes, H1
  8. Number of Products by Stage and Mechanism of Actions, H1
  9. Number of Products by Stage and Route of Administration, H1
  10. Number of Products by Stage and Molecule Type, H1
  11. Pipeline by AngioChem Inc, H1
  12. Pipeline by ArmaGen Inc, H1
  13. Pipeline by Bioasis Technologies Inc, H1
  14. Pipeline by Green Cross Corp, H1
  15. Pipeline by JCR Pharmaceuticals Co Ltd, H1
  16. Pipeline by Laboratorios Del Dr Esteve SA, H1
  17. Pipeline by RegenxBio Inc, H1
  18. Pipeline by Sangamo Therapeutics Inc, H1
  19. Pipeline by Shire Plc, H1
List of Figures:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Top 10 Indications, H1
  4. Number of Products by Mechanism of Actions, H1
  5. Number of Products by Stage and Mechanism of Actions, H1
  6. Number of Products by Routes of Administration, H1
  7. Number of Products by Stage and Routes of Administration, H1
  8. Number of Products by Molecule Types, H1
  9. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AngioChem Inc
  • ArmaGen Inc
  • Bioasis Technologies Inc
  • Green Cross Corp
  • JCR Pharmaceuticals Co Ltd
  • Laboratorios Del Dr Esteve SA
  • RegenxBio Inc
  • Sangamo Therapeutics Inc
  • Shire Plc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll